Hayden Kathleen M, Zandi Peter P, Lyketsos Constantine G, Tschanz JoAnn T, Norton Maria C, Khachaturian Ara S, Pieper Carl F, Welsh-Bohmer Kathleen A, Breitner John C S
Center for the Study of Aging and Human Development, Duke University Medical Center, Durham, North Carolina.
J Am Geriatr Soc. 2005 Jun;53(6):935-42. doi: 10.1111/j.1532-5415.2005.53301.x.
To evaluate the association between apolipoprotein E (apo E) epsilon4 and mortality, the population attributable risk for mortality with epsilon4, and relative contributions of cardiovascular disease (CVD) and Alzheimer's disease (AD).
Population-based cohort study.
Community-based.
Permanent residents of Cache County, Utah, aged 65 and older as of January 1, 1995.
Participants were genotyped at the apo E locus using buccal-swab deoxyribonucleic acid. Cardiovascular health was ascertained using self- or proxy-report interviews at participants' residences. AD was diagnosed according to Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised, and National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders criteria. Utah Department of Vital Statistics quarterly reports were reviewed to identify participants who died.
Crude evaluations showed nonsignificantly greater risk of death for epsilon2/2 (hazard ratio (HR)=1.66, 95% confidence interval (CI)=0.92-2.76) and epsilon3/4 (HR=1.11, 95% CI=0.97-1.26) genotypes and significantly greater risk for epsilon4/4 (HR=1.48, 95% CI=1.09-1.96). After adjustment for age, age(2), sex, and education, risks increased to 1.98 (95% CI=1.08-3.35), 1.28 (95% CI=1.12-1.46), and 2.02 (95% CI=1.47-2.71), respectively, compared with epsilon3/3 genotypes. Adjustment for presence of any CVD did not change the risk of death for epsilon3/4 and epsilon4/4. Adjustment for AD reduced the risk of death for epsilon3/4 (HR=1.13, 95% CI=0.99-1.30) and epsilon4/4 (HR=1.59, 95% CI=1.15-2.14). The population attributable risk of death for epsilon3/4 and epsilon4/4 genotypes combined is estimated at 9.6%.
These findings suggested that the epsilon2/2, epsilon3/4, and epsilon4/4 genotypes have greater early mortality risks. Further analyses showed that AD partially mediates the association between epsilon3/4, epsilon4/4, and death.
评估载脂蛋白E(apo E)ε4与死亡率之间的关联、ε4导致死亡的人群归因风险,以及心血管疾病(CVD)和阿尔茨海默病(AD)的相对贡献。
基于人群的队列研究。
以社区为基础。
截至1995年1月1日,犹他州卡什县65岁及以上的永久居民。
使用口腔拭子脱氧核糖核酸对参与者的apo E基因座进行基因分型。通过在参与者家中进行的自我报告或代理报告访谈来确定心血管健康状况。根据《精神障碍诊断与统计手册》第三版修订本以及美国国立神经疾病和中风研究所-阿尔茨海默病及相关疾病标准诊断AD。查阅犹他州生命统计部的季度报告以确定死亡的参与者。
粗略评估显示,ε2/2基因型(风险比(HR)=1.66,95%置信区间(CI)=0.92 - 2.76)和ε3/4基因型(HR = 1.11,95% CI = 0.97 - 1.26)的死亡风险略高但无统计学意义,而ε4/4基因型的死亡风险显著更高(HR = 1.48,95% CI = 1.09 - 1.96)。在对年龄、年龄²、性别和教育程度进行调整后,与ε3/3基因型相比,风险分别增至1.98(95% CI = 1.08 - 3.35)、1.28(95% CI = 1.12 - 1.46)和2.02(95% CI = 1.47 - 2.71)。对是否存在任何CVD进行调整后,ε3/4和ε4/4的死亡风险未改变。对AD进行调整后,ε3/4(HR = 1.13,95% CI = 0.99 - 1.30)和ε4/4(HR = 1.59,95% CI = 1.15 - 2.14)的死亡风险降低。ε3/4和ε4/4基因型合并导致死亡的人群归因风险估计为9.6%。
这些发现表明,ε2/2、ε3/4和ε4/4基因型具有更高的早期死亡风险。进一步分析表明,AD部分介导了ε3/4、ε4/4与死亡之间的关联。